Compare Coinbase Global, Inc. (COIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Merck & Co., Inc. — how do they compare? Coinbase Global, Inc. trades at $163.5 (market cap $42.55B), while Merck & Co., Inc. trades at $123.48 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 7× Coinbase Global, Inc.'s market cap, and Merck & Co., Inc. pays a 2.82% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| COIN | MRK | |
|---|---|---|
Market Cap | $42.55B | $298.31B |
Sector | Technology | Health |
52-Week High | $419.78 | $129.52 |
52-Week Low | $141.09 | $77.60 |
Enterprise Value | $39.83B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $157.37, down 1.07% on the day, with bearish technical signals from moving averages and a neutral RSI. The company reported mixed Q1 2026 earnings, missing estimates, but maintains strong revenue growth with 2025 revenue of $7.18 billion and net income of $1.26 billion. Recent news highlights regulatory developments and a leadership transition, with the Chief Legal Officer stepping down in July 2026.
The stock presents a high-risk opportunity with Wall Street analysts maintaining a bullish consensus price target of $228.62, implying significant upside. Key risks include earnings volatility, regulatory uncertainty, and competitive pressures. Investors should weigh the company's solid cash flow generation against its elevated valuation multiples and recent earnings misses.
Merck (MRK) trades at $123.45, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, including Q1 2026, and the company is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 forecasts show a decline in profitability.
The outlook remains positive with a consensus price target of $137.30, offering ~11% upside. Key risks include increased debt levels, competitive pressures in oncology, and potential regulatory hurdles from acquisitions. Institutional buying activity supports confidence, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
